Pharmacology of Lebrikizumab (Ebglyss); Mechanism of action, Uses, Effects, Pharmacokinetics

Fri, 29 Aug 2025 12:15:36 +0000

Lebrikizumab (Ebglyss) is a monoclonal antibody that targets interleukin-13 (IL-13), a cytokine involved in atopic dermatitis (eczema). It is used for moderate-to-severe atopic dermatitis in patients who require systemic therapy2.

Pharmacology
Mechanism of Action:

Lebrikizumab binds to IL-13, preventing its interaction with IL-13 receptors.

This reduces inflammation and improves skin barrier function.

Absorption: Administered subcutaneously, with peak levels reached in 6 days.

Metabolism: Cleared via proteolytic degradation.

Elimination: Slow clearance, with a half-life of ~23 days.

Clinical Uses
Atopic Dermatitis: Approved for moderate-to-severe cases.

Investigated for other inflammatory conditions.

Adverse Effects
Conjunctivitis & keratitis (eye inflammation).

Injection site reactions (pain, redness, swelling).

Herpes zoster infections (reported in clinical trials).

Avoid live vaccines during treatment

#Lebrikizumab